Beam Therapeutics Inc.
Developing precision genetic medicines using base editing to provide cures for serious diseases.
BEAM | NDAQ
Overview
Corporate Details
- ISIN(s):
- US07373V1052
- LEI:
- Country:
- United States of America
- Address:
- 26 LANDSDOWNE STREET, 2139 CAMBRIDGE
- Website:
- https://beamtx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Beam Therapeutics is a biotechnology company pioneering the development of precision genetic medicines through its proprietary base editing technology. Launched in 2018, the company utilizes a next-generation CRISPR platform designed to make precise, single-letter edits to the genome without creating double-stranded breaks in the DNA. Beam's mission is to provide lifelong cures for patients with serious diseases, focusing on genetic disorders, hematological conditions, and oncology. The company is building a fully integrated platform with a diverse suite of delivery technologies, including viral, nonviral, and electroporation modalities, to advance its portfolio of investigational therapies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
Automate Your Workflow. Get a real-time feed of all Beam Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Beam Therapeutics Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Beam Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
